Wang, Y <br/><br/>
Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.  [electronic resource] 

 -  Cell death & disease  May 2014 
 - e1227 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2041-4889 
<br/><br/><label>Standard No.: </label>10.1038/cddis.2014.186  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cyclin B1--genetics<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm<br/>Epithelial-Mesenchymal Transition--drug effects<br/>Gefitinib<br/>HEK293 Cells<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--drug therapy<br/>Mice<br/>Mice, Nude<br/>MicroRNAs--metabolism<br/>Neoplasm Invasiveness<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins--genetics<br/>Quinazolines--pharmacology<br/>RNA Interference<br/>Receptor Protein-Tyrosine Kinases--metabolism<br/>Time Factors<br/>Transfection<br/>Tumor Burden--drug effects<br/>Wnt Proteins--genetics<br/>Wnt-5a Protein<br/>Xenograft Model Antitumor Assays<br/>Axl Receptor Tyrosine Kinase